Asgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off.
Read moreThe world wealthiest look for cellular reprogramming as the key for longevity with limitless funds for research
Read more“A growing interest in the field and even a fear of missing out on a revolutionary approach.”
Read moreAsgard Therapeutics AB announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Read moreSmiLe Incubator company Asgard Therapeutics collaborates with Lund University and two European contract research organizations in the project REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer. The three-year proposal was ranked #4 out of 644 European applications for Eurostars Cut off 15, and is thereby securing a grant of 2 million euros.
Read moreThe 2021 Merck EU Advance Biotech Grants Program aims to support emerging biotech companies pushing innovative drugs to the market by allowing grant recipients to receive free products and services.
Read moreAsgard Therapeutics project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Skåne University Hospital and Lund University was awarded with Sweden’s SWElife innovation grant.
Read moreIn a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.
Read more@MicheleTavecchio has joined Asgard Therapeutics as Senior Scientist to work on the In vivo validation of cell reprogramming technologies. Michele is a successful scientist with international acquired experience in the fields of Cancer Pharmacology and Therapy.
Our Co-Founder and Head of research Fábio Fiúza Rosa will be sharing and reflecting on Asgard Therapeutics key research and journey to date at Science After Work today at Medicon Village.
https://www.mediconvillage.se/sv/node/3611
#innovationinhealthcare #asgardthx #Smile
Reprogramming Star Cristiana Pires unveils the career path that lead her to the stellar position of CEO and Co-founder at Asgard Therapeutics in this month issue of Cellular Reprogramming.
https://www.liebertpub.com/doi/full/10.1089/cell.2022.29061.cp#.Yk3BoqRCceI.twitter
Asgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off. https://www.linkedin.com/feed/update/urn:li:activity:6917003006345375745
Top marks for CEO coaching in collaboration between Almi and SmiLe
Asgard Therapeutics team is expanding. We are actively seeking for a Project Director for Preclinical Pharmacology. If you are looking for a career developing new cancer immunotherapies by exploiting direct in-vivo cell fate reprogramming, apply now
https://www.linkedin.com/jobs/view/project-director-preclinical-pharmacology-at-asgard-therapeutics-2948857415/?originalSubdomain=se
Today, Asgard Therapeutics reaches a major research milestone in the development of its lead gene therapy product - TrojanDC. Find out more in this new study from our scientific founders showing increased human cell conversion efficiency from 1% to 60%.
https://www.science.org/doi/10.1126/sciimmunol.abg5539
Cell Reprogramming is getting hot! via @Labiotech_eu
Today, we are pleased to announce EUR 6M in Seed Financing co-led by @novoholdings, @Boehringer Ingelheim Venture Fund and @Industrifonden. This seed round will enable the exploitation of direct in vivo #reprogramming for #CancerImmunotherapy.
Full PR:
Today, we are pleased to announce EUR 6M in Seed Financing co-led by @novoholdings, @Boehringer Ingelheim Venture Fund and @Industrifonden. This seed round will enable the exploitation of direct in vivo #reprogramming for #CancerImmunotherapy.
Full PR:
;